Total Knee Arthroplasty
Conditions
Interventions
Test group:Imrecoxib Tablets
control group:Placebo
Sponsors
The second affiliated hospital Zhejaing University school of medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Consent to sign informed consent; 2. The total knee arthroplasty was performed under general anesthesia, and 48h morphine analgesia was needed after surgery; 3. The age of the patient must be in 18-80 years old, male or female; 4. ASA classification must be I or II; 5. Patients with knee osteoarthritis must be treated for the first time with total knee arthroplasty; 6. No cognitive impairment communication difficulties or mental and neurological diseases.
Exclusion criteria
Exclusion criteria: 1. They are known to have been allergic to cox-2 inhibitors, sulfonamide, morphine or administration of anesthetics; 2. Patients treated with total knee arthroplasty; 3. Long-term use of sedative analgesic drugs or the history of chronic pain other than knee joint; 4. Patients with abnormal coagulation function; 5. There are any of the following: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, metastatic carcinoma, and Paget disease; 6. Weight <40kg or BMI is not between 18kg/m2-30kg/m2; 7. Oral administration, intramuscular injection hormone and intramuscular injection of hormone in 1 month before surgery; 8. For the first six hours before surgery, a drug with a cox-2 inhibitor, NSAIDS, and a drug that causes pain loss within 24 hours of surgery; 9. Having a history of alcoholism or history of drug addiction; 10. Severe liver and renal insufficiency; 11. Patients with severe diabetes complications, uncontrollable angina pectoris, uncontrollable arrhythmias, and severe heart failure history; 12. Active esophagus, stomach, pylorus or duodenal ulcer/hemorrhage, or recurrent ulcer/hemorrhagic patients; 13. Active esophagus, stomach, pylorus or duodenal ulcer/hemorrhage, or recurrent ulcer/hemorrhagic patients; 14. Some researchers think it is not appropriate to use experimental drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The total amount of tramadol was used in the two groups at 96h after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| The VAS score in patients at 6h?24h?48h?96h after surgery;Consumption of tramadol;The overall evaluation of patients for analgesia;Consumption of morphine;The levels of il-1ß, il-6 and il-8 protein markers;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactShigui Yan
The Second Affiliated Hospital Zhejaing University School of Medicine
Outcome results
None listed